# LCA System Comprehensive Demonstration

Generated: 2026-01-28 22:55:28

```

================================================================================
  1. ONTOLOGY INTEGRATION
================================================================================

--- LUCADA Ontology ---
    Status: Created successfully
    Classes: 68
    Core classes: Patient, ClinicalFinding, TreatmentPlan, Procedure

--- SNOMED-CT Integration ---
    Lung cancer concepts: 44 concepts
    Histology mappings: 7 types
    TNM Stage mappings: 7 stages
    Example: Adenocarcinoma -> 35917007

--- LOINC Integration ---
    Status: Active
    Local mappings: 17 lab tests
    Example mappings:
        - EGFR Mutation: LOINC 21639-1
        - ALK FISH: LOINC 81466-9
        - PD-L1 TPS: LOINC 85147-0

--- RxNorm Integration ---
    Status: Active
    Drug mappings: 22 oncology drugs
    Example mappings:
        - Pembrolizumab: RxNorm 1547220
        - Osimertinib: RxNorm 1721468
        - Carboplatin: RxNorm 40048

--- Clinical Guidelines ---
    Rules loaded: 10
    Source: NICE Lung Cancer Guidelines 2011 (CG121)
    Error: slice(None, 3, None)

================================================================================
  2. AGENT ARCHITECTURE (14 Agents)
================================================================================

--- Core Processing Agents ---
    [IngestionAgent] Data validation & normalization
        Status: Initialized
    [SemanticMappingAgent] SNOMED-CT mapping
        Status: Initialized
    [ClassificationAgent] Guideline classification
        Status: Initialized
    [ExplanationAgent] MDT summary generation
        Status: Initialized

--- Specialized Clinical Agents ---
    [BiomarkerAgent] Precision medicine recommendations
        Status: Initialized
    [NSCLCAgent] NSCLC-specific pathways
        Status: Initialized
    [SCLCAgent] SCLC-specific protocols
        Status: Initialized
    [ComorbidityAgent] Safety assessment
        Status: Initialized
    [ConflictResolutionAgent] Multi-agent consensus
        Status: Initialized

--- Analytics Agents ---
    [UncertaintyQuantifier] Bayesian confidence estimation
    [SurvivalAnalyzer] Kaplan-Meier + Cox regression
    [ClinicalTrialMatcher] ClinicalTrials.gov API integration
    [CounterfactualEngine] What-if scenario analysis

--- Orchestration Agents ---
    [DynamicOrchestrator] Complexity-based adaptive routing
    [IntegratedWorkflow] 14-agent orchestration

================================================================================
  3. PATIENT ANALYSIS
================================================================================

--- Patient Profile ---
    ID: DEMO_PATIENT_001
    Age: 68, Sex: M
    Stage: IIIA
    Histology: Adenocarcinoma
    Performance Status: WHO 1
    Comorbidities: Hypertension, Type 2 Diabetes, Atrial Fibrillation
    Biomarkers:
        - egfr_mutation: Exon 19 deletion
        - alk_rearrangement: Negative
        - pdl1_tps: 45
        - kras_mutation: Negative

--- Processing with Full AI Workflow ---

--- Results ---
    Workflow Type: integrated
    Complexity: critical
    Execution Time: 9583ms
    Provenance ID: prov_DEMO_PATIENT_001_20260128_172513
  
  Recommendations (1):
        1. Concurrent chemoradiotherapy followed by durvalumab
             Rule: nsclc_agent | Evidence: Grade A
             Intent: curative | Confidence: 90%

--- MDT Summary ---
    68 year old M patient diagnosed with Adenocarcinoma of the lung (Right side) at TNM Stage IIIA. ECOG Performance Status is 1. Based on NICE guidelines, this case is classified as 'Concurrent chemoradiotherapy followed by durvalumab' with 90% confidence.

================================================================================
  4. DIGITAL TWIN ENGINE
================================================================================

--- Initializing Digital Twin ---
    Twin ID: twin_DEMO_PATIENT_001_cff531f1
    State: active
    Context Graph: 1 nodes, 0 edges

--- Simulating Clinical Update ---
    Update processed: 0 alerts generated

--- Trajectory Predictions ---
    - Continue current therapy - stable disease
        Probability: 58%, PFS: 8.3mo
  
  Overall Confidence: 50%

================================================================================
  5. ADVANCED ANALYTICS
================================================================================

--- Survival Analysis ---
    Method: Kaplan-Meier + Cox Proportional Hazards
    Output: Survival curves, hazard ratios, risk stratification
    Example: Median survival = 287.0 days

--- Uncertainty Quantification ---
    Method: Bayesian + Historical outcomes
    Metrics: Epistemic, Aleatoric, Total uncertainty
    Output: Confidence intervals, reliability scores

--- Clinical Trial Matching ---
    Source: ClinicalTrials.gov API
    Matching: Histology, Stage, Biomarkers, PS
    Found 2 matching trials:
        - NCT12345678: Phase 3 Study of Osimertinib in EGFR-Mutant NSCLC...
            Match: 50% | Recommended - Good eligibility match, review criteria
        - NCT87654321: Pembrolizumab + Chemotherapy vs Chemotherapy in PD...
            Match: 50% | Recommended - Good eligibility match, review criteria

--- Counterfactual Analysis ---
    Scenarios: Biomarker changes, Earlier detection
    Output: Alternative treatment paths, outcome changes

================================================================================
  6. DATABASE & GRAPH INTEGRATION
================================================================================

--- Neo4j Graph Database ---
    URI: bolt://localhost:7687
    Status: Connected
    Node types: Patient, ClinicalFinding, Histology, TreatmentPlan
    Relationships: HAS_CLINICAL_FINDING, HAS_HISTOLOGY, AFFECTS

--- Vector Store ---
    Model: all-MiniLM-L6-v2 (384 dimensions)
    Index: clinical_guidelines_vector
    Use: Semantic guideline search

--- Graph Algorithms ---
    Available: Node Similarity, Pathfinding
    Use: Finding clinically similar patients

--- Provenance Tracking ---
    Standard: W3C PROV-DM
    Entities: Patient, Recommendations, Workflows
    Activities: Agent executions, Data transformations

================================================================================
  7. MCP SERVER (Model Context Protocol)
================================================================================
    Purpose: Claude AI Integration
    Port: 3000
    Tools: 60+ exposed tools

--- Tool Categories ---
    - Patient Management: CRUD operations, validation
    - Guideline Matching: Semantic search, rule application
    - Agent Execution: Run specialized agents
    - Analytics: Survival, uncertainty, trials
    - Graph Queries: Similar patients, temporal analysis
    - Export: PDF, FHIR, JSON formats
  
  To start: python start_mcp_server.py
    Configure: Add to claude_desktop_config.json

================================================================================
  DEMONSTRATION SUMMARY
================================================================================
    Total execution time: 173.1 seconds
    Components tested: 7 major subsystems
    Agents active: 14
    Ontologies loaded: 4 (LUCADA, SNOMED-CT, LOINC, RxNorm)
```
